This is an aggregated industry headline. Read the full story at Drug Channels →
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Since this article was published last December, Net Pricing Drug Channel developments have accelerated. Manufacturers reduced the list prices
By Drug Channels
· Apr 8, 2026
· via Drug Channels
Tags
policyformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFiercePharma ↗
The U.S. Supreme Court has temporarily reinstated online access to the abortion pill mifepristone after a fede…
PolicySTAT News ↗
A key GOP lawmaker is broadening the party's efforts to combat health care fraud.…
PolicyBriefing
The final rule adds disclosure requirements for SSBCI benefits but eases prior consumer protection measures ar…